3. Umbruch 4.4..2005 - Online Pot

106 J. Fernández-Ruiz et al.
fonylester (–)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY
38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol
Exp Ther 302: 359–368
111 Sinor AD, Irvin SM, Greenberg DA (2000) Endocannabinoids protect cerebral cortical neurons
from in vitro ischemia in rats. Neurosci Lett 278: 157–160
112 Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di
Marzo V, Mechoulam R (1998) An entourage effect: inactive endogenous fatty acid glycerol
esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353: 23–31
113 Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA (2002) Increased severity of stroke
in CB1 cannabinoid receptor knock-out mice. J Neurosci 22: 9771–9775
114 Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A (2002)
Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled,
phase II clinical trial. Crit Care Med 30: 548–554
115 Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G, van Dijk JG, Topper R,
Schwartz M, Roos RA (1999) Pathophysiology of chorea and bradykinesia in Huntington’s disease.
Mov Disord 14: 398–403
116 Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipion S (2001) Loss of normal
huntingtin function: new developments in Huntington’s disease research. Trends Neurosci 24:
182–188
117 Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes in the basal ganglia
circuitry in Parkinson’s disease. Prog Neurobiol 62: 63–88
118 Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease – a double-edged
sword. Neuron 35: 419–432
119 Rieckmann P, Smith KJ (2001) Multiple sclerosis: more than inflammation and demyelination.
Trends Neurosci 24: 435–437
120 Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, Filippi M (2002)
Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol 1:
499–509
121 Yong VW (2004) Prospects for neuroprotection in multiple sclerosis. Front. Bioscience 9:
864–872
122 Carri MT, Ferri A, Cozzolino M, Calabrese L, Rotilio G (2003) Neurodegeneration in amyotrophic
lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res
Bull 61: 365–374
123 Strong M, Rosenfeld J (2003) Amyotrophic lateral sclerosis: a review of current concepts.
Amyotroph Lateral Scler Other Motor Neuron Disord 4: 136–143
124 Lastres-Becker I, Hansen HH, Berrendero F, de Miguel R, Pérez-Rosado A, Manzanares J,
Ramos JA, Fernández-Ruiz J (2002) Loss of cannabinoid CB1 receptors and alleviation of motor
hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of
Huntington’s disease. Synapse 44: 23–35
125 Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J
(2003) Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia
in a rat model of Huntington’s disease. J Neurochem 84: 1097–1109
126 Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ (1997) Effects of dronabinol on anorexia
and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 12:
913–919
127 Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000)
Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404: 84–87
128 Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward
L, Fezza F, Bisogno T, Di Marzo V (2001) Endocannabinoids control spasticity in experimental
multiple sclerosis. FASEB J 15: 300–302
129 Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJ, Brown P, Bridges D, Ledent C, Bifulco
M, Rice AS et al. (2002) Arvanil-induced inhibition of spasticity and persistent pain: evidence for
therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2
receptors. Eur J Pharmacol 439: 83–92
130 de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D,
Fernandez-Ruiz J, Di Marzo V (2004) In vivo pharmacological actions of two novel inhibitors of
anandamide cellular uptake. Eur J Pharmacol 484: 249–257
131 Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000) Enhanced levels of endo-